Aurdan Capital Management LLC Acquires New Shares in Stryker Co. (NYSE:SYK)

Aurdan Capital Management LLC purchased a new position in Stryker Co. (NYSE:SYK) in the fourth quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund purchased 867 shares of the medical technology company’s stock, valued at approximately $312,000.

A number of other institutional investors and hedge funds also recently made changes to their positions in SYK. Kohmann Bosshard Financial Services LLC acquired a new stake in shares of Stryker in the fourth quarter worth about $25,000. Rakuten Securities Inc. lifted its position in shares of Stryker by 618.2% in the fourth quarter. Rakuten Securities Inc. now owns 79 shares of the medical technology company’s stock worth $28,000 after buying an additional 68 shares during the last quarter. Centricity Wealth Management LLC acquired a new stake in shares of Stryker in the fourth quarter worth about $30,000. BankPlus Trust Department acquired a new stake in shares of Stryker in the fourth quarter worth about $33,000. Finally, Activest Wealth Management acquired a new stake in shares of Stryker in the fourth quarter worth about $36,000. Institutional investors and hedge funds own 77.09% of the company’s stock.

Stryker Price Performance

Shares of NYSE:SYK opened at $377.01 on Friday. Stryker Co. has a 1-year low of $314.93 and a 1-year high of $406.19. The firm has a market capitalization of $143.90 billion, a PE ratio of 48.58, a PEG ratio of 2.93 and a beta of 0.93. The business’s 50 day moving average is $368.06 and its 200-day moving average is $376.10. The company has a current ratio of 1.95, a quick ratio of 1.32 and a debt-to-equity ratio of 0.59.

Stryker (NYSE:SYK) last announced its quarterly earnings data on Thursday, May 1st. The medical technology company reported $2.84 earnings per share for the quarter, topping the consensus estimate of $2.73 by $0.11. Stryker had a return on equity of 23.58% and a net margin of 13.25%. The company had revenue of $5.87 billion for the quarter, compared to analyst estimates of $5.68 billion. During the same quarter last year, the firm earned $2.50 EPS. Stryker’s revenue for the quarter was up 11.9% compared to the same quarter last year. Sell-side analysts predict that Stryker Co. will post 13.47 earnings per share for the current year.

Stryker Announces Dividend

The business also recently declared a quarterly dividend, which will be paid on Thursday, July 31st. Investors of record on Monday, June 30th will be paid a $0.84 dividend. This represents a $3.36 annualized dividend and a yield of 0.89%. The ex-dividend date of this dividend is Monday, June 30th. Stryker’s dividend payout ratio is 45.41%.

Analyst Upgrades and Downgrades

A number of analysts have weighed in on SYK shares. Needham & Company LLC reaffirmed a “buy” rating and issued a $442.00 price target on shares of Stryker in a research report on Friday, March 21st. Wall Street Zen downgraded Stryker from a “buy” rating to a “hold” rating in a research note on Thursday, March 6th. JMP Securities reaffirmed a “market perform” rating on shares of Stryker in a report on Monday, May 5th. JPMorgan Chase & Co. raised their target price on Stryker from $420.00 to $445.00 and gave the company an “overweight” rating in a report on Wednesday, January 29th. Finally, Royal Bank of Canada raised their target price on Stryker from $425.00 to $435.00 and gave the company an “outperform” rating in a report on Wednesday, January 29th. Five equities research analysts have rated the stock with a hold rating and fifteen have issued a buy rating to the stock. Based on data from MarketBeat, Stryker currently has an average rating of “Moderate Buy” and an average price target of $427.30.

Insider Activity at Stryker

In related news, Director Ronda E. Stryker sold 200,000 shares of the business’s stock in a transaction on Tuesday, May 6th. The stock was sold at an average price of $376.96, for a total value of $75,392,000.00. Following the sale, the director now owns 3,417,326 shares of the company’s stock, valued at $1,288,195,208.96. The trade was a 5.53% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. 5.90% of the stock is owned by insiders.

Stryker Profile

Stryker Corporation operates as a medical technology company. The company operates through two segments, MedSurg and Neurotechnology, and Orthopaedics and Spine. The Orthopaedics and Spine segment provides implants for use in total joint replacements, such as hip, knee and shoulder, and trauma and extremities surgeries.